Werewolf Therapeutics, Inc. (HOWL)
Automate Your Wheel Strategy on HOWL
With Tiblio's Option Bot, you can configure your own wheel strategy including HOWL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOWL
- Rev/Share 0.0
- Book/Share 0.9218
- PB 1.7195
- Debt/Equity 0.2422
- CurrentRatio 5.3022
- ROIC -0.9091
- MktCap 72474754.0
- FreeCF/Share -1.355
- PFCF -1.189
- PE -0.9747
- Debt/Assets 0.1085
- DivYield 0
- ROE -1.1187
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Details for the poster presentations are as follows:
Read More
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year –
Read More
About Werewolf Therapeutics, Inc. (HOWL)
- IPO Date 2021-04-30
- Website https://werewolftx.com
- Industry Biotechnology
- CEO Daniel J. Hicklin
- Employees 46